TOKYO, July 31, 2025 - (JCN Newswire via SeaPRwire.com) - TANAKA PRECIOUS METAL GROUP Co., Ltd. (Headquarters: Chuo-ku, Tokyo; Group CEO: Koichiro Tanaka) has decided to enter into a business partnership with JEPLAN, INC. (Headquarters: Kawasaki City, Kanagawa; Representative Director, President, and Chief Executive Officer: Masaki Takao; hereinafter “JEPLAN”) to reduce CO₂ emissions and promote the recycling organic materials in the precious metal recovery processes of TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd., a company engaged in precious metals business.This initiative represents a collaboration between TANAKA, committed to advancing a circular economy in the precious metals field, and JEPLAN, which has been pursuing similar goals in the plastics field, with both companies aiming to achieve a decarbonized, circular society.TANAKA’s Initiatives Thus Far for Realizing a Circular SocietySince its founding in 1885, TANAKA has been a leader in the precious metals industry, actively engaged in recycling these limited and valuable resources. Among the process waste materials received from customers who request recycling, those containing organic materials (plastics) as main components with precious metals attached or adsorbed have traditionally been processed through incineration to remove the organic materials, with precious metals then recovered from the ash left behind.While this incineration process has addressed the removal of environmentally regulated substances, the reduction of CO₂ generated during the combustion of organic materials has become a major challenge in realizing a decarbonized society.Transforming the Precious Metal Recovery Process Through a Business Partnership with JEPLANJEPLAN has established proprietary chemical recycling technology for polyethylene terephthalate, a type of plastic. To address the aforementioned CO₂ emissions issue, TANAKA is considering using chemical recycling in the future, in addition to the conventional precious metal recovery process through incineration. This initiative is being explored through a business partnership with JEPLAN. The materials targeted for chemical processing include plastics such as syringes and wiping cloths. CO₂ emissions from the targeted precious metal recovery process are expected to be reduced to approximately 10% of conventional levels.In addition, this process enables not only precious metal recovery, but also plastic regeneration, with TANAKA and JEPLAN each contributing to the realization of a decarbonized, circular society through their respective areas of expertise.JEPLAN, INC. ( https://www.jeplan.co.jp/en/ )Representative: Masaki Takao, Representative Director, President, and Chief Executive OfficerEstablished: January 2007Main Business: Business based and related to PET chemical recycling technology (for PET bottles, polyester), etc.The JEPLAN Group aims to realize a circular economy with its mission of "We circulate our world." We use our proprietary PET chemical recycling technology to break down waste PET (PET bottles, polyester fibers, etc.) into molecules and remove impurities, regenerating it into recycled materials of the same quality as petroleum-derived materials. Through our recycling efforts using this proprietary technology, we are realizing the recycling of limited resources and contributing to the reduction of CO₂ emissions.The JEPLAN Group operates PET chemical recycling plants at two locations, PET REFINE TECHNOLOGY CO., LTD. (Kawasaki City, Kanagawa Prefecture, for PET bottles) and Kitakyushu Hibikinada Plant (Kitakyushu City, Fukuoka Prefecture, for polyester fibers), and is also promoting technology licensing in Japan and overseas.About TANAKASince its foundation in 1885, TANAKA has built a portfolio of products to support a diversified range of business uses focused on precious metals. TANAKA is a leader in Japan regarding the volume of precious metals it handles. Over many years, TANAKA has manufactured and sold precious metal products for industry and provided precious metals in such forms as jewelry and assets. As precious metals specialists, all Group companies in Japan and worldwide collaborate on manufacturing, sales, and technology development to offer a full range of products and services. With 5,591 employees, the group’s consolidated net sales for the fiscal year ending December 2024, was 846.9 billion yen.TANAKA Industrial Precious Metal Materials Portalhttps://tanaka-preciousmetals.comProduct inquiriesTANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-on-industrial-products/Press inquiriesTANAKA PRECIOUS METAL GROUP Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-for-media/Press release: https://www.acnnewswire.com/docs/files/20250731.pdf   Copyright 2025 JCN Newswire via SeaPRwire.com.

KARIYA, JAPAN, July 31, 2024 - (JCN Newswire via SeaPRwire.com) - DENSO, a leading mobility supplier, today announced global financial results for the first quarter, ending June 30, 2025, of its fiscal year, ending March 31, 2026:Consolidated revenue totaled 1,754.1 billion yen (US$11.7 billion), remaining consistent with the previous year.Consolidated operating profit totaled 107.2 billion yen (US$0.7 billion), an 11.1 percent decrease from the previous year.Consolidated profit attributable to owners of the parent company totaled 79.3 billion yen(US$0.5 billion), a 16.1 percent decrease from the previous year.“Revenue in the first quarter remained consistent with the previous year, driven by a strong increase in vehicle sales in Japan, despite a decline in revenue due to the impact of the strong yen.” said Yasushi Matsui, CFO, Executive Vice President and member of the Board of Directors of DENSO CORPORATION.“In this fiscal year, we forecast 7,200.0 billion yen (US$48.2 billion) in revenue and 675.0 billion yen (US$4.5 billion) in operating profit. Forecast of revenue will be based on reflecting the results of the first quarter, and the expected increase in revenue due to the reflection of tariff costs from the second quarter onwards. Operating profit forecast remains unchanged supported by efforts to minimize the impact of tariff costs and to steadily reflect incurred costs in pricing. Furthermore, as part of measures to enhance corporate value, it was resolved to sell DENSO’s own shares in Toyota Industries Corporation (“Toyota Industries”) and to provide advance notice of a tender offer for its own shares held by Toyota Industries.”In Japan, revenue increased to 1,013.3 billion yen (US$6.8 billion), up 2.9% from the previous year, and operating profit decreased to 13.3 billion yen (US$89.3 million), down 70.4％ from the previous year.In North America, revenue decreased to 473.2 billion yen (US$3.2 billion), down 5.4％ from the previous year, and operating profit decreased to 22.6 billion yen (US$151.1 million) down 3.0％ from the previous year.In Europe, revenue decreased to 186.9 billion yen (US$1.3 billion), down 6.4% from the previous year, and operating profit increased to 5.2 billion yen (US$34.9 million), up 4.4% from the previous year.In Asia, revenue decreased to 459.0 billion yen (US$3.1 billion), down 0.5％ from the previous year and operating profit increased to 47.7 billion yen (US$318.8 million), up 33.3% from the previous year.In other areas, revenue increased to 30.1 billion yen (US$0.2 billion), up 4.0％ from the previous year, and operating profit decreased to 5.5 billion yen (US$36.9 million), down 7.3％ from the previous year.For more details, please see the link below (detailed data).https://www.denso.com/global/en/news/newsroom/2025/20250731-g02/About DENSO CORPORATIONGlobally headquartered in Kariya, Japan, DENSO is a 7,161.8 billion yen leading mobility supplier that develops advanced technology and components for nearly every vehicle make and model on the road today. With manufacturing at its core, DENSO invests in around 180 facilities worldwide to provide opportunities for rewarding careers and to produce cutting-edge electrification, powertrain, thermal and mobility electronics products, among others, that change how the world moves. In developing such solutions, the company’s 158,000 global employees are paving the way to a mobility future that improves lives, eliminates traffic accidents, and preserves the environment. DENSO spent around 8.6 percent of its global consolidated sales on research and development in the fiscal year ending March 31, 2025. For more information about DENSO’s operations worldwide, visit https://www.denso.com/global Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, Japan, July 31, 2025 - (JCN Newswire via SeaPRwire.com) –Honda Motor Co., Ltd. today launched a teaser page on its company website to share information on the all-new Prelude, which is scheduled to go on sale in September 2025.The all-new Prelude is a specialty sports model which represents the unrelenting Honda sports mindset, carrying forward the “joy of driving” into the electrified era, while also pursuing environmental performance and everyday usability.All-New Prelude Teaser Page: https://www.honda.co.jp/PRELUDE/new/All-new PreludeOverview of all-new PreludeGrand Concept: “Unlimited Glide” — Endless driving pleasure & Extraordinary experience —Inspired by the image of gliders soaring freely and boundlessly through the open sky, Honda developed the all-new Prelude under the grand concept of “Unlimited Glide,” striving for a vehicle that evokes the uplifting sensation of gliding gracefully through the air and extraordinary experience that people do not have in their everyday lives.Like a glider, with proportions that epitomize a universally recognized functional beauty with widespread wings and which glides through the air while making dynamic yet smooth turns, the all-new Prelude was designed to offer a special driving experience that arouses the desire to keep on driving. Equipped with a further advanced e:HEV, original Honda hybrid system, this model will become the “prelude” for future Honda specialty sports models in the electrified era. Exterior designThe all-new Prelude features a low, sharp front nose and smooth, yet expressive body lines, which contribute to the uplifting sensation of gliding through the air, as well as a low and wide stance that evokes a sense of dynamic driving. Moreover, this model is characterized by a number of unique design features such as the headlight design inspired by gliders, smooth and clean door panels with flush outer door handles, and the black chrome-plated front grille that express the sense of premium quality and sophistication, embodying what Honda pursues in its specialty cars.Interior designDesign evoking the uplifting sensation of gliding through the air was also applied to the interior of the all-new Prelude, ensuring a comfortable space not only for the driver but the front passenger as well. The grand concept of the all-new Prelude was expressed with the main interior color combination of fresh white and deep blue. The instrument panel design evokes a sense of exclusivity through its fine detailing such as the softly shaded white surface material that makes it irresistible to touch and the embroidered Prelude logo in front of the passenger seat.The front seats were designed differently to suit separate needs: the driver’s seat holds the driver in place even during sporty driving, while the passenger seat offers comfort together with just the right amount of feeling of being enveloped. Other unique interior design features, such as a low and horizontally expansive line of sight, a D-shaped steering wheel and full-graphic meters designed exclusively for Prelude, are enhancing a sense of anticipation for an exceptional driving experience this vehicle can offer.Package designAs a new-generation specialty car that offers new value to the customer, the all-new Prelude features a package design that achieves seemingly conflicting qualities—specialty and versatility.While a wide, low and smoothly sculpted body realizes the proportions worthy of a specialty sports model, the large-diameter tires and an optimized wheelbase enable the all-new Prelude to demonstrate its outstanding dynamic performance.In addition, a cargo space features a large-opening liftback that makes loading and unloading easy, split-folding rear seats that enable versatile cargo loading, as well as an underfloor storage compartment and convenient hooks, to realize a user-friendly cargo space. History of Honda PreludeEver since the launch of the first-generation model in 1978, spanning five generations, Honda Prelude has always been at the forefront of the times as an advanced FF (front-engine, front-wheel-drive) specialty model featuring cutting-edge technologies of the times, including: the first Japanese model to feature an electric sunroof, anti-lock brake system (ABS), and the world’s first four-wheel steering (4WS) system. After a 24-year hiatus, with this 6th-generation model, the Prelude will return to the market as a hybrid specialty car suitable for the electrified era. Copyright 2025 JCN Newswire via SeaPRwire.com.

Developing dual-use UAVs for civil and defense applicationsAutomating the transport of heavy cargo with MHI's multi-purpose medium-sized UAVAccelerating the transport of medications using a VTOL (vertical take-off and landing) UAV capable of flying long distances at high speedTOKYO, July 31, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) participated in a practical training exercise held on July 17 at the Japan Ground Self-Defense Force (JGSDF) Asaka Garrison (Nerima-ku, Tokyo), aimed at improving response capabilities in the event of an earthquake centered on the Tokyo metropolitan area. The training was conducted by the JGSDF Eastern Army in cooperation with local governments, with MHI joining at the request of the Japan UAS Industrial Development Association (JUIDA). MHI conducted training to transport relief supplies to isolated disaster victims using its medium-sized multirotor uncrewed aerial vehicle (hereinafter "medium-sized UAV") currently being developed by its Commercial Aviation Systems division, and the VTOL (vertical take-off and landing) UAV being developed by the Integrated Defense & Space Systems division.The medium-sized UAV is being developed for a variety of purposes, such as transporting relief supplies in the event of a disaster, providing logistics support to remote islands and mountainous areas, and conveying materials for construction work on power transmission towers. It has conveyance functionality with enhanced wind resistance during takeoff and cruising, and an automatic unloading function that allows the cargo to be lowered at the destination with a winch from a hovering state without having to land. For this exercise, MHI conducted a loading demonstration of relief supplies, and a flight demonstration. Going forward, MHI will pursue further functional improvements such as incorporation of satellite communication capabilities, and extension of the cruising range with a hybrid power system.(Note)The VTOL UAV is being developed for the purpose of quickly delivering relief supplies to remote islands and ships in transit. It is capable of high speed flight over long distances of up to 1,000 kilometers, and can take off and land even in places without runways. For this exercise, MHI took advantage of the maneuverability and vertical take-off and landing capabilities of the VTOL UAV to demonstrate quick delivery of medicines to disaster areas.MHI will continue to pursue the development of dual-use UAVs with consideration for both civil and defense applications, and through their use, work to provide solutions for various societal challenges.Medium-sized UAV used during training for the transport of relief suppliesVTOL UAV used during training for the transport of relief suppliesNote: Using an engine to generate electricity.Specifications of the Medium-Sized UAVPayload (maximum): 200kgCruising range: 15km (battery type), 200km (hybrid type under development)Dimensions: Overall length approx. 6mMotive power: Battery type, Hybrid type (under development)Ease of transport: Can be transported by truck to takeoff/landing pointsAdditional equipment for demonstration testing: Automatic unloading system using a winch, relief supplies transport containerSpecifications of the VTOL UAVPayload (maximum): 5kgCruising range: 1,000kmDimensions: Overall length approx. 2.4m, main wingspan 3.4mMotive power: For fixed-wing propulsion: EngineFor multicopter: Electric motorsAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2025 JCN Newswire via SeaPRwire.com.

- Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer’s Disease- 56% of Patients with Low Tau Continued to Demonstrate Improved Cognitive and Daily Living Function at Four YearsTOKYO and CAMBRIDGE, Mass., July 31, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”)and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher,“Biogen”) announced today that the latest findings demonstrating the benefits of continuous treatment with lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer’s disease (AD), were presented at the Alzheimer's Association International Conference(AAIC) 2025, held in Toronto, Canada, and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.Four Years of Lecanemab Therapy Helped Patients Slow the Progression of AD and Remain in the Early Stages of AD Longer Compared to AD’s Natural Course Clarity AD is a global Phase 3 placebo-controlled, double-blind, parallel-group, randomized study to evaluate lecanemab 10 mg/kg bi-weekly IV treatment of early Alzheimer's disease, which involved 1,795 patients(treatment group: 898, placebo group: 897). 95% of patients who completed the core study (18 months) chose to continue in the open-label extension study (OLE), with 478 patients still receiving treatment for four years. In the Clarity AD core study, the mean change from baseline between the lecanemab treated group and the placebo group after 18 months was -0.45 (P=0.00005) on the primary endpoint of CDR-SB global cognitive and functional scale.To provide context, a change from 0.5 to 1 on the Clinical Dementia Rating (CDR) score domains of Memory, Community Affairs and Home/Hobbies reflects a shift from mild impairment to loss of independence. This can affect a person’s ability to be left alone safely, recall recent events, participate in daily activities, manage household tasks, and engage in hobbies and intellectual interests.1,2Over three years of treatment, including both the core study and the OLE, data showed lecanemab demonstrate da reduction in cognitive decline—measured by CDR-SB—of 1.01 points compared to the expected decline observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI)** cohort. This benefit grew more pronounced after four years, with a reduction of 1.75 points. Similarly, when bench marked against the expected decline in the BioFINDER*** cohort, lecanemab showed a reduction of 1.40 points at three years and an even greater reduction of 2.17 points at the four years mark. For more details, please visit: https://www.eisai.com/news/2025/pdf/enews202554pdf.pdfMEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@Eisai.comBiogen Inc.Madeleine Shin+1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+ 1-781-464-2442IR@biogen.com  Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO and CAMBRIDGE, Mass., July 31, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”)and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher,“Biogen”) announced today that results on investigational maintenance therapy with subcutaneous autoinjector (SCAI) of lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer’s disease (AD), were presented at the Alzheimer's Association International Conference(AAIC) 2025, held in Toronto, and virtually. Only lecanemab fights AD in two ways—targeting both protofibrils and plaque, which can impact tau accumulation downstream.Importance of Ongoing Treatment and SC Development ProgramDue to the reaccumulation of AD biomarkers and return to placebo rate of decline after therapy is stopped1, Eisai is investigating a new lecanemab SC maintenance treatment option following 18 months of IV therapy so patients can continue to fight this progressive, relentless disease.Clinical trials of lecanemab SC were conducted as a sub-study of the open-label extension (OLE) following the core Phase 3 Clarity AD study in individuals with early AD, to evaluate a range of doses administered by SC vial or autoinjector. Eisai has developed a SC-AI for maintenance therapy at a dose of 360 mg weekly and a500 mg SC-AI is being developed for initiation dosing. Similar Impact on Clinical Outcomes and Biomarkers with IV and SC DosingThe pharmacology (PK/PD), clinical (efficacy endpoints such as CDR-SB) and biomarker (amyloid PET and blood biomarkers) relationships established with extensive clinical data supported the FDA approval of IV maintenance therapy after the initial 18 months of treatment and support the investigational SC maintenance dose option.- Data supports that transitioning to a weekly 360 mg SC AI dose of lecanemab after 18 months of initiation dose (10 mg/kg IV biweekly) maintains clinical and biomarker benefits comparable to continued biweekly IV dosing.- Clinical and biomarker responses at 48 months with monthly IV maintenance dosing are similar to the responses with ongoing biweekly dosing whether patients are amyloid positive (>30 CL) or negative (<30 CL) at 18 months.- Data shows the 500 mg SC AI has equivalent exposure as the initial treatment regimen of 10mg/kg IV biweekly up to 18 months for amyloid removal, efficacy, and ARIA-E.Safety MattersThe safety profile of 360 mg weekly SC maintenance dosing was shown to be consistent with that of IV maintenance therapy, with <1% systemic injection/infusion reactions. Across all SC doses, the rate of systemic injection/infusion reactions is 1% compared to 26% with IV. The 360 mg SC maintenance dose was initiated after 18 months of IV treatment, beyond the high-risk period for ARIA. There were 0 cases of ARIA-E observed out of 49 treated with 360 mg SC weekly maintenance for a mean of 6 months.Study Participants Successfully Administered SC-AI and Found it Easy to UseTo optimize the safe and effective use of SC autoinjector (SC-AI), additional studies were conducted, including a human factors (HF) study and a tolerability assessment of the device.The HF Study involved 110 participants (63 early AD patients, 32 care partners, and 15 healthcare professionals: HCPs) to assess the appropriate administration of lecanemab SC-AI. Overall, 95% (104/110) of participants successfully administered the maintenance dose. The Autoinjector Device Acceptability Study involved 126 participants (25 early AD patients, 50 care partners, and 51 HCPs), to evaluate the device's ease of use, convenience and feasibility of administration. As an interim outcome, over 95% of participants reported that the SC-AI is easy to administer. They were highly satisfied with it and had no concerns about administration, even at home. Furthermore, all patients responded that they welcomed the introduction of SC-AI.These studies and evaluations of lecanemab SC-AI have demonstrated that the investigational SC-AI offers efficacy and safety comparable to IV administration with the potential to reduce the incidence of infusion site adverse events. From the perspective of patients and care partners, benefits included the ability to use the device at home, shortening treatment time, and to continue treatment without having to worry about visiting an infusion center. From the perspective of HCPs, they reported that the device has the potential to provide a new option for patients who are benefiting from lecanemab to continue the treatment. The SC formulation has the potential to reduce medical preparation and administration time related to IV therapy. These factors suggest that the SC AI may play an important role in continuing treatment for early AD.This release is based on the content of the presentations given at AAIC, "Featured Research Session #4-13-FRS-C: Lecanemab Subcutaneous Formulation for Maintenance Dosing: The Potential of a New and Convenient Option for Ongoing Treatment in Early Alzheimer’s Disease," held at 9:00 AM on Wednesday, July 30, and also includes some content from the Developing Topics session held at 8:00 AM on Sunday, July 27,entitled "Patient, Care Partner, and Health Care Professional Opinion of the Lecanemab Autoinjector for Subcutaneous Delivery in Early Alzheimer's Disease Patients."Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.* Protofibrils are thought to be the most toxic AB species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal and synaptic damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms.1 The mechanism by which this occurs has been reported not only by increasing the formation of insoluble AB plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD. 2For more details, please visit: https://www.eisai.com/news/2025/pdf/enews202553pdf.pdfMEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@Eisai.comBiogen Inc.Madeleine Shin+1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+ 1-781-464-2442IR@biogen.com  Copyright 2025 JCN Newswire via SeaPRwire.com.

Santa Clara, CA, July 29, 2025, (ACN Newswire via SeaPRwire.com) - Meshy.ai, the world’s leading AI-powered 3D content generation platform, has launched the Meshy 5 Preview, offering early access to the next generation of AI 3D model generator. Built on the strong foundation of Meshy 4, this preview version introduces smarter generation tools, enhanced image alignment, sharper geometry, and over 500 new animations—empowering creators to build faster, cleaner, and more creatively than ever before.Trusted by 3 Million Creators – The Platform of Choice for Game DevelopersWith over 30 million 3D assets generated and a community of more than 3 million creators, Meshy has become the go-to AI platform for game developers, VFX artists, and 3D content professionals worldwide. Recognized by Andreessen Horowitz (a16z) as the only 3D tool featured in its list of “Most Popular AI Tools Among Game Developers,” Meshy is redefining how digital worlds are built—with speed, accuracy, and creative control.What’s New in Meshy 5 PreviewStronger Image Alignment: Mesh structures now more precisely match the shape and proportions of input images — with support for multi-view input to generate more complete 3D models.Razor-sharp Geometry: From hard-surface mechs to organic characters, edges are sharper and forms more defined.Advanced AI Tools: Now supports Kontext for multi-view generation and a smart AI Prompt Helper to make prompting faster and easier.500+ New Animations: A dramatically expanded animation library for rigged characters, empowering developers and artists with more expressive motion capabilities.“The multi-view support and sharper geometry have made our modelling workflow twice as fast with much less cleanup,” said Victoria C., a senior 3D environment artist at an indie game studio and early Meshy 5 Preview tester. “This version brings us much closer to using AI directly in our production pipeline.”From Meshy 4 to Meshy 5 Preview: A Foundation ReinforcedAbout one year ago, Meshy introduced Meshy 4, which brought improvements in geometry quality, Text to 3D workflow, and retry functionality. Meshy 5 Preview builds on that foundation, offering enhanced mesh coherence, fewer visual defects, and a more structured modelling-to-texturing pipeline—allowing creators to move from concept to completion with unprecedented speed and clarity.Whether generating stylized concepts or rigged production assets, Meshy empowers studios to accelerate creative pipelines, reduce manual workloads, and retain full artistic control. The platform integrates seamlessly with tools like Unity, Unreal Engine, Blender, and ZBrush, and supports advanced rigging and animation workflows out-of-the-box.What Sets Meshy ApartPowered by cutting-edge foundation models, Meshy combines advanced AI technology with industry-leading product capabilities to deliver unparalleled value. Its unique features and user-centric design have established Meshy as the world’s leading AI 3D model generator. Key differentiators include:Hyper-Realistic Texture Generation – Capable of producing highly detailed, natural-looking textures that align with industry standards.Advanced Rigging and Animation Support – Offers ready-to-use rigged models alongside an expanding motion library, significantly streamlining animation workflows.A Thriving Community for Remix & Creative Collaboration – Hosts a vast repository of high-quality, customizable assets, enabling creators to easily remix and build upon existing work.Unmatched Workflow Flexibility – Supports both white and textured model outputs, along with texture swapping via text or images. Artists can effortlessly re-style assets — for example, transforming a realistic model into an ink-wash aesthetic — without starting from scratch.Real Creators. Real Workflows. Real Impact.From indie game developers and VFX artists to educators and avatar designers, creators around the world are embracing Meshy 5 Preview to reimagine the way they build, teach, and tell stories in 3D. Whether it’s speeding up asset production, unlocking new creative directions, or making 3D design accessible to more people—Meshy is becoming a core part of real-world workflows.Explore how Meshy is powering next-gen creativity—one creator at a time.Sivan Okcu – Avatar Creator for Second LifeUses Meshy’s Text to 3D and Image to 3D features to produce stylized avatars faster, reduce costs, and grow his virtual business.“I can explore more styles, lower prices, and sell more—all without sacrificing quality.” Read Sivan’s story → Skylyfe Inc. – Tech Education for Underserved YouthEmpowers students aged 10–30 with hands-on 3D design using Meshy in an 8-week program focused on 3D printing, AR, and VR.“Students said it felt like printing things from your mind into real life.”Read the Skylyfe story → Marcos Medel – VFX Artist & AnimatorTransforms classical paintings into surreal 3D cinematic loops using Meshy to create custom models with AI-enhanced workflows.“Something that could take days or weeks — Meshy can do in just a few clicks.” Read Marcos’s story → David Zhang – Indie Game Developer (Remnants of R’lyeh) Builds weapons, creatures, and deep-sea props using Meshy’s Text-to-3D, accelerating production and enriching a Lovecraft-inspired horror world.“Meshy helped bring my game’s vision to life—faster, cheaper, and more creatively.” Read David’s story → Read More User Stories in the Meshy BlogWhether you’re a creator with a cool workflow or an influencer interested in collaborating, share your project with us at marketing@meshy.ai.Media Contact: Conan Zhang, Meshy.ai, marketing@meshy.ai, www.meshy.ai Distributed by Pinion Newswire. All rights reserved. Copyright 2025 JCN Newswire via SeaPRwire.com.

TOYOTA CITY, July 30, 2025 - (JCN Newswire via SeaPRwire.com) - Toyota Motor Corporation announces its sales, production, and export results for June 2025 as well as the cumulative total from January to June 2025, including those for subsidiaries Daihatsu Motor Co., Ltd. and Hino Motors, Ltd.For more details, please see the link below (detailed data).Click here for detailed sales, production, and export results ("Detailed data (Excel)")URL https://global.toyota/en/company/profile/production-sales-figures/202506.html  Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO and CAMBRIDGE, Mass., July 31, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,“Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-AB protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways– targeting both amyloid plaque and protofibrils*, which can impact tau downstream.Lecanemab received traditional approval in the U.S. in July 2023 for the treatment of early Alzheimer's disease (AD). This retrospective study was conducted to investigate the actual state of real-world clinical treatment with lecanemabat 15 medical centers in the U.S., with a final report scheduled for late in the third quarter of Eisai’s fiscal year ending March 31, 2026. This presentation serves as an interim report as of July 1, 2025.Patient Baseline and Actual Treatment Situation The interim study collected information on 178 people living with early AD from nine US medical centers using a standardized case report format. The disease stage of the patients at baseline was mild cognitive impairment (MCI) due to AD in 57.6% and mild AD in 42.4%. The average age of the patients was 74.2 (±6.6) years, and the ratio of men to women was 44.6 to 55.4.The mean duration of lecanemab treatment was 375.4 days (± 182.8 days). The mean time from diagnosis to first treatment was 224.2 days (± 295.4 days) and the mean number of lecanemab treatments was 24.8 (± 11.5). At the time of case reporting, 87.4% of patients (152 patients) were continuing treatment with lecanemab. Adverse events leading to discontinuation of treatment included ARIA-E (ARIA-edema/exudation) in two patients (1.1%), ARIA-H(ARIA-cerebral microbleeds, cerebral hemorrhage and superficial hemosiderin deposition) in two patients (1.1%),and concomitant ARIA-E and ARIA-H in one patient (0.6%). Three patients (1.7%) discontinued due to adverse events other than ARIA. In addition, 11 patients (6.3%) reported discontinuing the treatment for personal reasons or at the discretion of their doctor or the individual.In this study, 83.6% of patients either remained at the same clinical stage or improved from mild dementia to MCI (stable: 76.9%, improvement: 6.7%). Additionally, at time of interim data cut, 86.7% of patients who had received 40 or more doses over 18 months remained stable or showed clinical improvement (stable: 66.7%,improvement: 20.0%:).Of the 178 patients, ARIA was observed in 23 (12.9%). 14 (7.9%) were observed to have ARIA-E, of which 12(6.7%) were asymptomatic. ARIA-H was present in 11 patients (6.2%), all of whom were asymptomatic. Infusion reactions were observed in four patients (2.2%). Additionally, no serious bleeding events or deaths were reported. Impact of APOE4 Status Of the 178 patients in this study, 12 were excluded with unknown status. Among the remaining 166 patients,30 (18.1%) were APOE 4 homozygotes, 84 (49.4%) were heterozygotes, 54 (32.5%) were non-carriers. Generally, the proportion of homozygotes among people with AD is thought to be 15% or more.The incidence of ARIA was 20.0%, 9.8% and 14.8% in homozygous carriers, heterozygous carriers and noncarriers, respectively (45.0%, 19.0% and 13.0% respectively in the Phase 3 Clarity AD 18-month core study). The incidence rate of ARIA-E and ARIA-H were 13.3% and 10.0%, respectively (32.6% and 39.0% in the Clarity AD core study), which is within the FDA-approved label range. The majority of ARIA cases (0.13%) were asymptomatic. The incidence of adverse events leading to discontinuation was 16.7% in homozygous carriers,2.4% in heterozygous carriers and 5.6% in non-carriers.73.3% of homozygote patients’ clinical stage remained stable or improved (stable: 66.6%, improved: 6.7%),88.0% of heterozygotes patients’ clinical stage remained stable or improved (stable: 83.0%, improved: 4.9%)and 85.2% of non-carrier patients’ clinical stage remained stable or improved (stable: 75.9%, improved: 9.3%).Utilization of Blood-Based Biomarkers (BBMs)BBMs are being developed in AD to identify brain AB pathology and are intended for use in prescreening (triage)and confirmatory diagnosis. Of the 178 patients in this study, 49 patients (27.5%) were diagnosed using BBMs. In some of these cases (11 patients, 6.1%), it was also used for confirmatory diagnosis. Data collected from clinical practices showed the volume of tests doubling every 4 to 8 months, with BBMs using p-tau217 growing most rapidly.Satisfaction with Lecanemab Treatment The results of a physician, patient and care partner lecanemab satisfaction survey was presented. The survey was based on questionnaires and interviews with nine U.S. physicians and evaluated treatment from multiple perspectives, including efficacy, safety and quality of life (QOL).In the physicians’ evaluation, the average satisfaction level for the treatment efficacy and safety (out of 10) was8.7. The scoring criteria included: cognition 8.1, daily function 8.1, behavioral/neuropsychiatric symptoms 7.9and QOL 8.0. The satisfaction level of the patients as assessed by physicians was 8.8, and that of the care partners was 8.2. These results highlight the favorable evaluation of lecanemab’s efficacy and safety in real world clinical practice and reinforce its therapeutic value.Note: Retrospective real-world studies can be very valuable in providing additional information to complement clinical trial data. However, there may have several limitations to keep in mind:Potential for BiasesData Completeness and ConsistencyData may be collected inconsistently since data collection is completed by different people at independent3 sites.* Mitigation: Data inconsistency is pursued by providing site access to standardized electronic case-report forms.Lack of Control GroupInterpretation of data may be limited since real-world studies do not utilize placebo-controlled armsConfounding VariablesConfounding variables are not controllable, which may impact the relationship between the exposure and outcome.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.* Protofibrils are thought to be the most toxic AB species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal and synaptic damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms.1 The mechanism by which this occurs has been reported not only by increasing the formation of insoluble AB plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD.2For more details, please visit: https://www.eisai.com/news/2025/pdf/enews202552pdf.pdfMEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@Eisai.comBiogen Inc.Madeleine Shin+1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+ 1-781-464-2442IR@biogen.com  Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, July 30, 2025 - (JCN Newswire via SeaPRwire.com) - Sharp Corporation has reached an agreement with Mitsubishi Chemical Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Manabu Tsukimoto), the National Institute of Information and Communications Technology (NICT) (Headquarters: Koganei City, Tokyo; President: Hideyuki Tokuda), and TECHLAB Co., Ltd. (Headquarters: Tama City, Tokyo; President: Hiroshi Hatakeyama) to collaboratively develop ultra-compact and lightweight LEO (Low Earth Orbit) satellite communication user terminals for mobility applications.Left: Ultra-Compact and Lightweight LEO Satellite Communication User Terminal;Right: An Image of the Terminal Installed in a VehicleLEO satellite communication enables high-quality, high-speed connectivity even in challenging environments such as mountainous regions, at sea, and on remote islands. Sharp began developing LEO satellite communication user terminals in 2023 (*2), applying design and communication technologies honed through smartphone development to create a compact model (approximately 446 x 446 x 66mm) weighing around 7kg. The goal of this agreement is to accelerate efforts towards practical implementation by fiscal 2025, targeting deployment on vessels and other platforms.With this new agreement, the development of even smaller and lighter LEO satellite communication user terminals will commence in collaboration with Mitsubishi Chemical, NICT, and TECHLAB. A form factor about one-tenth the size (approximately 200 x 200 x 30mm and 1kg) of the currently developed terminal will be aimed through the development of lightweight, high thermal conductivity composite materials and superior heat dissipation designs. By enabling deployment on mobility platforms such as drones and vehicles, applications of LEO satellite communication will be significantly expanded, ensuring communication lines in mountainous areas and disaster zones, enabling real-time location data transmission, and facilitating usage in autonomous vehicles.This initiative will be showcased at the Sharp booth (*2) (South Exhibition Hall, Satellite Data and Space Utilization Area S6-34) and at the Mitsubishi Chemical booth (S7-11) during the "SPEXA - [International] Space Business Exhibition 2025," held at Tokyo Big Sight (Koto-ku, Tokyo) from July 30 (Wednesday) to August 1 (Friday).Roles of Parties Involved- Sharp: Development of LEO satellite communication user terminals utilizing miniaturization and communication technologies cultivated in smartphone design.- Mitsubishi Chemical: Development of new lightweight, high thermal conductivity composite materials for heat dissipation plates.- NICT: Overall design and simulation of antennas for ultra-miniaturization and lightweight structures, including heat dissipation designs.- TECHLAB: Material molding and processing of new materials.Contacts:NTN_B5G@sharp.co.jp*1 This terminal integrates LEO satellite communication antennas and modem functions. LEO stands for Low Earth Orbit.*2 The development of LEO satellite communication user terminals and participation in SPEXA is supported by a grant from the National Institute of Information and Communications Technology (NICT). (JPJ012368G50501)  Copyright 2025 JCN Newswire via SeaPRwire.com.

Mitsubishi Heavy Industries aims to integrate DCIM (Data Center Infrastructure Management) into its One-stop solutions portfolio to offer digital services to data centersThe combination delivers a comprehensive view of data center infrastructure, enabling enhanced visibility, elevated operational efficiency and optimized energy consumptionTOKYO, July 29, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) has concluded an agreement with Modius® Inc., a US based provider of innovative software solutions for managing critical facilities for the data center and telecommunications markets. Under this agreement, MHI will integrate Modius's OpenData® DCIM technology with MHI's power, cooling, and control technologies to deliver a unique, market leading solution for Data Center Energy Management (DCEM). This collaboration is an example of MHI Group's partnering efforts, and MHI Group will continue to build strategic partnerships globally.Modius's OpenData DCIM platform provides real-time insights into data center infrastructure, enabling capacity management, improved uptime and enhanced energy efficiency. With over 250 deployments worldwide, Modius has gained customer trust for delivering reliable and sustainable solutions that optimize operations and reduce environmental impact.With rapid scaling of digital infrastructure globally and frequent upgrades to IT systems, it is becoming an overwhelming challenge to manage the reliable operation of data centers while also being energy efficient. The OpenData® AI/ML module strengthens MHI's One-stop Solutions Portfolio by enabling real-time anomaly detection and proactive diagnostics. By self-learning the "normal" behavior of data centers, the AI system empowers operators to address issues before they escalate. By combining Modius's real time monitoring and AI/ML driven analytics with MHI's cutting-edge engineering solutions, the joint offering will empower customers to proactively manage capacity, minimize downtime, and improve sustainability."MHI is committed to delivering sustainable and energy efficient data center solutions," said Shin Gomi, Senior General Manager, DCEM at MHI. "With the addition of the Modius DCIM platform to our digital solution portfolio, we can offer digital services to both existing and new customers seeking enhanced visibility and optimization for building next-generation data centers.""MHI's global presence and its alignment with our mission to drive efficiency, improve sustainability, and optimize performance in data centers make this collaboration a perfect fit," said Craig Compiano, President at Modius. "We are excited to work with MHI to deliver our DCIM solutions alongside their advanced technologies to customers worldwide.Mitsubishi Heavy Industries Group is delivering more sustainable and reliable solutions to data centers by combining decarbonized power generation, reliable power distribution, high efficiency cooling systems and Integrated Digital Solutions. We support our customers through the complete lifecycle from design phase to post deployment with actionable insights, solutions and services.About ModiusModius Inc. is a leading innovator in Data Center Infrastructure Management (DCIM) solutions, providing real-time visibility and decision support for managing distributed equipment across data centers, telecommunications networks, and other critical facilities. The company's flagship product, OpenData, is an edge-ready asset performance management platform designed to optimize the availability, capacity, and efficiency of critical infrastructure. For more information about Modius Inc. and the OpenData platform, please visit Modius.comAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2025 JCN Newswire via SeaPRwire.com.